Compare NWN & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NWN | HRMY |
|---|---|---|
| Founded | 1859 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | N/A | 2020 |
| Metric | NWN | HRMY |
|---|---|---|
| Price | $46.77 | $36.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $49.50 | ★ $49.75 |
| AVG Volume (30 Days) | 241.2K | ★ 615.1K |
| Earning Date | 02-27-2026 | 02-24-2026 |
| Dividend Yield | ★ 4.18% | N/A |
| EPS Growth | 20.18 | ★ 50.44 |
| EPS | 2.47 | ★ 3.17 |
| Revenue | ★ $1,266,082,000.00 | $825,944,000.00 |
| Revenue This Year | $15.18 | $23.29 |
| Revenue Next Year | $6.55 | $15.98 |
| P/E Ratio | $19.04 | ★ $11.58 |
| Revenue Growth | 11.27 | ★ 21.13 |
| 52 Week Low | $38.94 | $25.52 |
| 52 Week High | $49.63 | $40.93 |
| Indicator | NWN | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 50.37 | 48.42 |
| Support Level | $46.35 | $35.16 |
| Resistance Level | $47.16 | $37.08 |
| Average True Range (ATR) | 0.78 | 1.43 |
| MACD | 0.06 | -0.21 |
| Stochastic Oscillator | 58.31 | 43.22 |
Northwest Natural Holding Co is a public natural gas service supplier operating in the U.S. Pacific Northwest. Its subsidiary, NW Natural, operates through the natural gas distribution segment, which purchases and distributes natural gas through which operates in Oregon and southwest Washington. The company operates in one reportable business segment, which is NW Natural's local gas distribution business and is referred to as the NGD segment. The company generates its revenue from residential, commercial, and industrial customers, the majority of which are in Oregon. Residential and commercial customers account for the vast majority of profitability.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.